Biocon still bullish on oral insulin despite clinical trial disappointment
This article was originally published in Scrip
Biocon, India's largest biotechnology company by revenue, has said that its oral insulin candidate IN-105 failed to meet the primary endpoint of a clinical study in India, although it continues to be upbeat about taking the drug forward via a partnership.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.